69 related articles for article (PubMed ID: 17449101)
21. EBNA-2 -deleted Epstein-Barr virus from P3HR-1 can infect rabbits with lower efficiency than prototype Epstein-Barr virus from B95-8.
Sano H; Nagata K; Kato K; Kanai K; Yamamoto K; Okuno K; Kuwamoto S; Higaki-Mori H; Sugihara H; Kato M; Murakami I; Kanzaki S; Hayashi K
Intervirology; 2013; 56(2):114-21. PubMed ID: 23295915
[TBL] [Abstract][Full Text] [Related]
22. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
23. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication.
Xing L; Kieff E
J Virol; 2007 Sep; 81(18):9967-75. PubMed ID: 17626073
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations.
Chu PG; Chang KL; Chen WG; Chen YY; Shibata D; Hayashi K; Bacchi C; Bacchi M; Weiss LM
Am J Pathol; 1999 Sep; 155(3):941-7. PubMed ID: 10487851
[TBL] [Abstract][Full Text] [Related]
26. The p542 gene encodes an autoantigen that cross-reacts with EBNA-1 of the Epstein Barr virus and which may be a heterogeneous nuclear ribonucleoprotein.
Rhodes GH; Valbracht JR; Nguyen MD; Vaughan JH
J Autoimmun; 1997 Oct; 10(5):447-54. PubMed ID: 9376072
[TBL] [Abstract][Full Text] [Related]
27. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
28. Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo.
Hammer D; Wild J; Ludwig C; Asbach B; Notka F; Wagner R
Hum Gene Ther; 2008 Jun; 19(6):622-34. PubMed ID: 18533892
[TBL] [Abstract][Full Text] [Related]
29. Human DNA tumor viruses generate alternative reading frame proteins through repeat sequence recoding.
Kwun HJ; Toptan T; Ramos da Silva S; Atkins JF; Moore PS; Chang Y
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4342-9. PubMed ID: 25271323
[TBL] [Abstract][Full Text] [Related]
30. Identification of major phosphorylation sites of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce latent membrane protein 1 cooperatively with EBNA-2 is regulated by phosphorylation.
Yokoyama A; Tanaka M; Matsuda G; Kato K; Kanamori M; Kawasaki H; Hirano H; Kitabayashi I; Ohki M; Hirai K; Kawaguchi Y
J Virol; 2001 Jun; 75(11):5119-28. PubMed ID: 11333893
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro.
Chen A; Divisconte M; Jiang X; Quink C; Wang F
J Virol; 2005 Apr; 79(7):4506-9. PubMed ID: 15767450
[TBL] [Abstract][Full Text] [Related]
32. The conserved domain CR2 of Epstein-Barr virus nuclear antigen leader protein is responsible not only for nuclear matrix association but also for nuclear localization.
Yokoyama A; Kawaguchi Y; Kitabayashi I; Ohki M; Hirai K
Virology; 2001 Jan; 279(2):401-13. PubMed ID: 11162796
[TBL] [Abstract][Full Text] [Related]
33. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.
Yamazaki M; Kitamura R; Kusano S; Eda H; Sato S; Okawa-Takatsuji M; Aotsuka S; Yanagi K
Clin Exp Immunol; 2005 Mar; 139(3):558-68. PubMed ID: 15730403
[TBL] [Abstract][Full Text] [Related]
34. Macavirus latency-associated protein evades immune detection through regulation of protein synthesis in cis depending upon its glycin/glutamate-rich domain.
Sorel O; Chen T; Myster F; Javaux J; Vanderplasschen A; Dewals BG
PLoS Pathog; 2017 Oct; 13(10):e1006691. PubMed ID: 29059246
[TBL] [Abstract][Full Text] [Related]
35. The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein.
Krauer KG; Buck M; Belzer DK; Flanagan J; Chojnowski GM; Sculley TB
Virology; 2004 Jan; 318(1):280-94. PubMed ID: 14972554
[TBL] [Abstract][Full Text] [Related]
36. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
Buckner FS; Wipke BT; Van Voorhis WC
Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
[TBL] [Abstract][Full Text] [Related]
37. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
[TBL] [Abstract][Full Text] [Related]
38. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1.
Apcher S; Komarova A; Daskalogianni C; Yin Y; Malbert-Colas L; Fåhraeus R
J Virol; 2009 Feb; 83(3):1289-98. PubMed ID: 19019958
[TBL] [Abstract][Full Text] [Related]
39. A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator.
Zaldumbide A; Weening S; Cramer SJ; Rabelink MJ; Verhaagen J; Hoeben RC
Biotechnol Lett; 2010 Jun; 32(6):749-54. PubMed ID: 20155386
[TBL] [Abstract][Full Text] [Related]
40. mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.
Tellam JT; Zhong J; Lekieffre L; Bhat P; Martinez M; Croft NP; Kaplan W; Tellam RL; Khanna R
PLoS Pathog; 2014 Oct; 10(10):e1004423. PubMed ID: 25299404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
